Adalimumab induced interstitial lung disease

Last revised by Dr David Luong on 12 Jul 2021

Adalimumab induced interstitial lung disease is a form of anti-TNF-induced diffuse interstitial lung disease from the broader category of drug induced lung disease. The disease occurs as a response to the disease modifying anti-rheumatic drug adalimumab or HumiraTM.


Exact mechanism of pulmonary toxicity is unclear with one thought being inhibition of inflammatory cells by anti-TNF drugs leading to unopposed activity of inflammatory cells resulting in characteristic changes of an interstitial pneumonitis. 

The form of lung injury can vary from acute lung injury (ALI) 2 to pulmonary fibrosis 3-4.

ADVERTISEMENT: Supporters see fewer/no ads

Updating… Please wait.

 Unable to process the form. Check for errors and try again.

 Thank you for updating your details.